The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | Perspectives on the management of low and high-risk MDS
Hege Garelius, MD, Sahlgrenska University Hospital, Göteborg, Sweden, talks on the management of patients with low and high-risk myelodysplastic syndromes (MDS). While the treatment of low-risk MDS is focused on improving the patient’s quality of life (QoL), high-risk MDS is usually managed like acute leukemias. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
